CSIMarket
 


Takeda Pharmaceutical Company Limited  (TAK)
Other Ticker:  
 

Takeda Pharmaceutical Limited's Total Debt to Equity

TAK's quarterly Total Debt to Equity and Total Debt, Equity growth


Due to debt repayement of 0% Takeda Pharmaceutical Limited improved Total Debt to Equity in forth quarter 2023 to 0.65, a new company low.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 123 other companies have achieved lower Total Debt to Equity than Takeda Pharmaceutical Limited in the IV Quarter 2023. While Total Debt to Equity total ranking has deteriorated compared to the third quarter 2023 from 1720 to 1782 .

Explain Debt to Equity Ratio?
What is the structure of TAK´s Total Debt?
How valuable is the TAK´s Equity?


TAK Total Debt to Equity (Mar 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Mar 31 2021)
IV. Quarter
Y / Y Equity Change -5.53 % -5.53 % -5.53 % -5.53 % -
Y / Y Total Debt Change -32.3 % -32.3 % -32.3 % -32.3 % -
Total Debt to Equity MRQ 0.65 0.65 0.65 0.65 0.9
TAK's Total Ranking # 1782 # 1720 # 1847 # 1847 # 0
Seq. Equity Change 0 % 0 % 0 % -5.53 % 0 %
Seq. Total Debt Change 0 % 0 % 0 % -32.3 % 0 %



Total Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 124
Healthcare Sector # 293
Overall Market # 1782


Total Debt to Equity Statistics
High Average Low
0.9 0.77 0.65
(Mar 31 2021)   (Mar 31 2023)




Financial Statements
Takeda Pharmaceutical Limited's Equity $ 44,025 Millions Visit TAK's Balance sheet
Takeda Pharmaceutical Limited's Total Debt $ 28,461 Millions Visit TAK's Balance sheet
Source of TAK's Sales Visit TAK's Sales by Geography


Cumulative Takeda Pharmaceutical Limited's Total Debt to Equity

TAK's Total Debt to Equity for the trailling 12 Months

TAK Total Debt to Equity

(Mar 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Mar 31 2021)
IV. Quarter
Y / Y Equity TTM Growth -5.53 % -5.53 % -5.53 % -5.53 % -
Y / Y Total Debt TTM Growth -32.3 % -32.3 % -32.3 % -32.3 % -
Total Debt to Equity TTM 0.65 0.71 0.78 0.84 0.9
Total Ranking TTM # 106 # 119 # 114 # 118 # 0
Seq. Equity TTM Growth 0 % 0 % 0 % -5.53 % 0 %
Seq. Total Debt TTM Growth 0 % 0 % 0 % -32.3 % 0 %


On the trailing twelve months basis Due to debt repayement of 0% Takeda Pharmaceutical Limited decreased Total Debt to Equity in the 12 months ending in IV Quarter 2023 to 0.65, a new company low.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 11, during the past 12 months, other companies have achieved lower Total Debt to Equity than Takeda Pharmaceutical Limited. While Total Debt to Equity total ranking has improved so far to 106, from total ranking in previous 12 month period at 119.

Explain Debt to Equity Ratio?
What is the structure of TAK´s Total Debt?
How valuable is the TAK´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 12
Healthcare Sector # 30
Within the Market # 106


trailing twelve months Total Debt to Equity Statistics
High Average Low
0.9 0.8 0.65
(Mar 31 2021)   (Mar 31 2023)




Companies with similar Total Debt to Equity in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Total Debt to EquityMar 31 2023 MRQ Total DebtMar 31 2023 MRQ Equity
Phibro Animal Health Corporation  1.77 $ 481.436  Millions$ 272.328  Millions
Sarepta Therapeutics Inc   1.73 $ 1,234.284  Millions$ 712.749  Millions
G1 Therapeutics Inc   1.72 $ 77.470  Millions$ 44.988  Millions
Jazz Pharmaceuticals Plc  1.72 $ 5,720.662  Millions$ 3,335.041  Millions
Eli Lilly And Company  1.67 $ 18,883.600  Millions$ 11,294.900  Millions
Panbela Therapeutics Inc   1.65 $ 4.194  Millions$ 2.535  Millions
Zoetis Inc   1.46 $ 6,562.000  Millions$ 4,491.000  Millions
Arcutis Biotherapeutics Inc   1.42 $ 198.763  Millions$ 139.732  Millions
Kala Bio inc   1.42 $ 33.266  Millions$ 23.461  Millions
Durect Corp  1.39 $ 21.303  Millions$ 15.342  Millions
Aptinyx Inc   1.37 $ 25.098  Millions$ 18.256  Millions
Trevena inc   1.33 $ 13.476  Millions$ 10.154  Millions
Axsome Therapeutics Inc   1.32 $ 147.615  Millions$ 111.812  Millions
Ionis Pharmaceuticals Inc  1.30 $ 631.836  Millions$ 486.570  Millions
Verastem inc   1.23 $ 40.578  Millions$ 33.025  Millions
Bristol myers Squibb Company  1.19 $ 37,830.000  Millions$ 31,886.000  Millions
Corbus Pharmaceuticals Holdings Inc   1.17 $ 19.184  Millions$ 16.459  Millions
Emergent Biosolutions Inc   1.16 $ 1,398.400  Millions$ 1,202.600  Millions
Vbi Vaccines Inc  1.10 $ 49.359  Millions$ 45.022  Millions
Spectrum Pharmaceuticals Inc   1.08 $ 28.840  Millions$ 26.805  Millions
Catalent Inc   1.03 $ 4,849.000  Millions$ 4,703.000  Millions
Tempest Therapeutics Inc   0.95 $ 10.416  Millions$ 10.965  Millions
Prestige Consumer Healthcare Inc   0.93 $ 1,345.788  Millions$ 1,447.084  Millions
Mustang Bio inc   0.93 $ 27.579  Millions$ 29.815  Millions
Ani Pharmaceuticals Inc  0.91 $ 286.307  Millions$ 314.632  Millions
Viatris Inc   0.90 $ 18,782.700  Millions$ 20,927.900  Millions
Milestone Pharmaceuticals inc   0.88 $ 47.320  Millions$ 53.935  Millions
Perrigo Company Plc  0.85 $ 4,101.600  Millions$ 4,833.900  Millions
Marinus Pharmaceuticals Inc   0.84 $ 71.498  Millions$ 85.085  Millions
Elanco Animal Health Inc  0.80 $ 6,020.000  Millions$ 7,480.000  Millions

Date modified: 2023-06-28T20:12:23+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com